

TABLE OF CONTENTS

Volume One

How to Use This Service

Table of Contents, Current Contents

Newsletters

Tab 100: Overview of Good Clinical Practice

Executive Summary	¶100
Overview of FDA Regulations.....	¶101
Regulatory Requirements for Drugs	¶102
Regulatory Requirements for Devices	¶103
Regulatory Requirements Applicable to	
Both Drugs and Devices	¶104
Other Federal Authorities.....	¶105
General Obligations of Sponsors	¶110
Regulatory Considerations for Sponsors	¶111
Product Liability Considerations for Sponsors.....	¶112
General Obligations of Monitors	¶120
Monitors' Responsibilities	¶121
Regulatory Considerations for Monitors	¶122
Product Liability Considerations for	
Monitors	¶123
Monitors' Obligations for Discontinued Studies	¶124
General Obligations of Clinical Investigators	¶130
Considerations in Large-scale or International	
Trials	¶140
Large-scale Trials.....	¶141
International Trials	¶142
FDA Acceptance of International Trials	¶143
Use of Contract Research Organizations	¶150
Institutional Review Boards	¶160
Major Considerations for Auditing Studies	¶170
Impact of Quality Assurance Audits on	
Business Decisions.....	¶171
Electronic Submissions to FDA	¶180
Computer Validation	¶181
Data Monitoring Committees	¶190

Tab 200: Investigator Obligations

Executive Summary	¶200
General Responsibilities of Investigators	¶201
FDA Form 1572 and Investigator's Agreement.....	¶202
Delegation of Authority for Data	
Management.....	¶203
FDA's Potential Enforcement Actions	¶204
Records Requirements for Investigators	¶210
Drug Study Records	¶211
Device Study Records.....	¶212
Records for Dispensing, Handling, and	
Shipping Articles.....	¶213
Record Retention Time Periods	¶214
Investigators' Reports	¶220
Drug Study Reports.....	¶221
Device Study Reports	¶222

Reporting Adverse Experiences	¶230
Reporting Adverse Experiences for Drugs	¶231
Reporting Adverse Experiences for Devices	¶232
Institutional Review Board Interactions	¶240
Laboratory Records	¶250
Laboratory Accreditation	¶251
Laboratory Samples	¶252
FDA's Process for Disqualifying Investigators	¶260
Situations That Can Lead to Disqualification	¶261
FDA Initiation of Investigator Inspections	¶262
Investigator's Response or Failure to Respond.....	¶263
FDA Decisions	¶264
FDA's Investigator Status Lists.....	¶265
FDA Debarment	¶270
What Debarment Means	¶271
Debarment of Individuals	¶272

Tab 300: Information About Subjects

Executive Summary	¶300
Medical History	¶310
Required Medical History Information.....	¶311
Study Articles	¶320
Blind Studies.....	¶321
Ongoing Clinical Evaluation	¶330
Test and Examination Results	¶331
Disease Progression	¶332
Response to Therapy.....	¶333
Concomitant Medication Information.....	¶334
Data Retention When Subjects Withdraw.....	¶335
Adverse Experiences	¶340
Collection of Race and Ethnicity Data	¶350

Tab 400: Document Requirements

Executive Summary	¶400
Source Documents	¶410
Source Document Checklist.....	¶411
Case Report Forms	¶420
Design of Case Report Forms	¶421
Completion of Case Report Forms	¶422
On-site Review of Case Report Forms	¶423
Corrections to Case Report Forms.....	¶424
Informed Consent	¶430
Long or Short Form	¶431
Procedures for Obtaining Consent in	
Emergencies	¶432
Required Elements	¶433
Additional Elements of Informed Consent	¶434
Notice That Trial Information Will Be Submitted	
to ClinicalTrials.gov.....	¶435
Execution of the Informed Consent	¶436
Common Form Deficiencies Identified	
by the FDA.....	¶437
Retention of Informed Consent Forms	¶438

Tab 400 (cont'd)

FDA Forms	¶440
Form FDA 1571	¶441
Form FDA 1572	¶442
Investigator Agreement	¶443
Sample Forms	¶444
IND Applications	¶445
IDE Applications	¶446
Clinical Trial Registration Certification	¶447
Investigational Article Reconciliation Records	¶450
Specific Requirements	¶451
Adverse Experience Reports	¶460
Adverse Experience Definitions for INDs	¶461
IND Safety Reports	¶462
Adverse Experience Definitions for IDEs	¶463
IDE Safety Reports	¶464
Global Adverse Event Reporting	¶465
Other Required Reports	¶470
IND Annual Reports	¶471
IDE Progress and Final Reports	¶472
Financial Disclosure/Certification	¶480
Sample Forms	¶481
Effective Procedures for Archiving Data	¶490

Tab 500: Sponsor/Monitor Obligations

Executive Summary	¶500
Basic Responsibilities of Sponsors	¶501
Basic Responsibilities of Monitors	¶502
Protocol Development	¶510
Phases of Investigations	¶511
Required Protocol Elements	¶512
Background Information and Objectives	¶513
Study Population	¶514
Study Plan and Procedures	¶515
Assessment of Data	¶516
List of Regulatory Requirements	¶517
Protocol Amendments	¶518
Special Protocol Assessment	¶519
Using Contract Research Organizations	¶520
General Considerations	¶521
Legal Considerations	¶522
Filing IND/IDE Applications	¶530
IND Applications	¶531
IND Amendments	¶532
IDE Applications	¶533
IDE Amendments	¶534
Sponsors' Obligations	¶540
Selecting Investigators	¶541
Informing Investigators: Initial and Ongoing Communication	¶542
Selecting Monitors	¶543
Establishing Standard Operating Procedures	¶544
Reporting Requirements	¶545
Data Review and Record Keeping	¶546
Study Article Preparation and Reconciliation	¶547
Clinical Trial Registration Certification	¶548
Monitors' Obligations	¶550
Pre-investigation Visits	¶551

Study Initiation Visits	¶552
Periodic Visits	¶553
Final Close-out Visits	¶554
Record of Monitoring Visits/Contacts	¶555
Checklists for Monitors	¶556
Monitoring Internal Documents	¶560

Tab 600: Evaluation of Clinical Data

Executive Summary	¶600
FDA Evaluation of Drug Trial Information	¶601
FDA Evaluation of Device Trial Information	¶602
FDA Guidelines for Evaluating Clinical Information	¶603
How to Assure Compliance with Protocol	¶610
Protocol Design	¶611
Investigator Training and Communication	¶612
Site Monitoring and Record Keeping	¶613
Data Capture vs. Protocol Requirements	¶614
Case Report Forms vs. Source Documents	¶615
Time and Event Relationships	¶616
Adverse Experiences	¶620
FDA Review of Risk- and Cost-benefit Data	¶630
Cost-benefit data	¶631
Quality of Life Data	¶632
FDA Review of Data Integrity	¶640
Data Auditing Responsibilities and Implications	¶641
Accelerated Approval of New Drugs, Antibiotics and Biologics	¶650
Initial Discussions and Preparation	¶651
Pre- and Post-marketing Studies	¶652
Distribution and Promotion Restrictions	¶653
Withdrawal of Approval	¶654
Emerging Issues in Accelerated Approvals	¶655

Tab 700: Quality Assurance Audits

Executive Summary	¶700
In-house Audits	¶710
Sponsor/Monitor Audits	¶711
Investigator File Audits	¶712
Investigator File Audit Checklist	¶713
Informed Consent Audits	¶714
Informed Consent Form Audit Checklist	¶715
Site Audits	¶720
Auditing Case Report Forms and Source Documents	¶721
Auditing Informed Consent Forms	¶722
Auditing Study Article Conditions	¶723
Auditing Facilities and Equipment	¶724
Auditing Site Personnel Qualifications and Training	¶725
Audit Follow-up and Reports	¶726
Clinical Audit Checklist	¶727
Contract Research Organization Audits	¶730
Audits of Study Reports	¶740
Reporting Audit Findings	¶750
Conforming Amendments	¶760

Table of Contents

Tab 800: Institutional Review Boards

Executive Summary	¶800
Clinical Studies Requiring IRB Monitoring	¶801
Clinical Studies Exempt from IRB Monitoring	¶802
FDA Requirements for IRBs	¶810
IRB Organization and Personnel	¶811
IRB Functions and Operations	¶812
IRB Review of Research	¶813
Expedited IRB Review	¶814
Criteria for IRB Approval	¶815
Records IRBs Must Maintain	¶816
IRB Registration	¶817
IRB Obligations to Ensure Informed Consent	¶820
IRB Obligations for Review of Clinical Trials	¶830
Ethical Considerations	¶840
Respect for Persons	¶841
Beneficence	¶842
Justice	¶843
Practical Considerations for IRBs	¶850
IRB Approvals	¶860
Non-local IRBs	¶870
Use of Non-local IRB	¶871
IRB Compliance and Noncompliance	¶880
IRB Inspections	¶881
Disqualification and Reinstatement of IRBs	¶882
IRB Responsibilities Under HIPAA	¶890

Tab 900: International Good Clinical Practice

Executive Summary	¶900
U.S. Agreements with Foreign Nations	¶901
European Union GCP	¶910
The Institutions of the European Union	¶911
EU Standards for Drug Clinical Trials	¶912
EU Standards for Device Clinical Trials	¶913
Is It a Clinical Trial Under EU Standards Decision Chart	¶914
Inspection Similarities and Differences: FDA and EMA	¶915
Japanese GCP	¶920
Canadian GCP	¶930
Comparison of FDA Regulations to International GCPs	¶940
EU Clinical Trial Directive Versus FDA Regulations	¶941
Japanese GCP Versus FDA Regulations	¶942
Canadian GCP Versus FDA Regulations	¶943
International Conference on Harmonisation	¶950
The ICH Process	¶951
ICH Guideline Topics	¶952
Sources of ICH and International GCP Information	¶953
Differences Between FDA Regulations and ICH GCP Guideline	¶954
Latin America GCP	¶960
Argentina	¶961

Mexico	¶962
Peru	¶963
Chile	¶964
Brazil	¶965
Colombia	¶966
Costa Rica	¶967
List of Regulatory Agencies in Latin America	¶968

Tab 1000: Electronic Submissions, Computer Validation

Executive Summary	¶1000
Scope and Application of Electronic Records and Signatures	¶1010
Data Entry	¶1020
Passwords	¶1021
Audit Trails	¶1022
Date/Time Stamps	¶1023
System Features	¶1030
Retrieval of Data	¶1031
Security	¶1040
Logical Security	¶1041
System Dependability	¶1050
Validation	¶1051
Documentation	¶1052
Change Control	¶1053
System Controls	¶1060
User Training	¶1070
Records Inspection	¶1080
Certification of Electronic Signatures	¶1090

Tab 1100: FDA Monitoring

Executive Summary	¶1100
FDA's Bioresearch Monitoring Program	¶1110
Types of Inspections	¶1111
Frequency of Inspections	¶1112
Results of Inspections Under Bioresearch Monitoring Program	¶1113
Overview of FDA Inspection Process	¶1120
Issuing Inspection Requests	¶1121
Verifying Data Integrity and Validity	¶1122
Verifying Monitoring and Clinical Investigators	¶1123
FDA's Clinical Investigations/Bioresearch Monitoring Branches	¶1130
Functions of Centers' Bioresearch Monitoring Divisions	¶1131
Inspection Classifications	¶1132
FDA Center Organizational Charts	¶1133
Responsibilities of FDA's District Offices	¶1140
District Offices' Role in Clinical Inspections	¶1141
FDA Administrative Actions	¶1150
Clinical Holds for INDs	¶1151
Resumption of IND Investigations	¶1152
Termination of INDs	¶1153
Inactive Status of INDs	¶1154
Disapproval or Withdrawal of IDEs	¶1155
FDA Regulatory Actions	¶1160

Tab 1200: Other Federal Authorities

Executive Summary	¶1200
Office for Civil Rights and HIPAA	¶1210
Privacy Rule	¶1211
Covered Entities	¶1212
Business Associates	¶1213
Protected Health Information	¶1214
Use and Disclosure of Protected Health Information	¶1215
Authorization for Research Uses and Disclosures	¶1216
Other Research Uses	¶1217
Individuals' Right to Privacy	¶1218
Breach Notifications	¶1219
Office for Human Research Protections	¶1220
OHRP Organizational Chart	¶1221
Division of Compliance Oversight	¶1222
Division of Education and Development	¶1223
Division of Policy and Assurances	¶1224
International Activities	¶1225
Secretary's Advisory Committee on Human Research Protections	¶1226
Office for Human Research Protections Decision Charts	¶1230
Centers for Medicare and Medicaid Services	¶1240
The 2000 Clinical Trial Policy	¶1241
Reconsideration of the Clinical Trial Policy	¶1242
The 2007 Clinical Trial Policy	¶1243
Coverage with Evidence Development	¶1244
Local Coverage Determination	¶1245
Sponsor Payment for Research-related Injuries	¶1246

Appendix I: Federal Statutes**Title 21 USC §301, et seq. — Federal Food, Drug, and Cosmetic Act, as Amended****Selected Sections**

- Chapter II — Definitions
- Chapter III — Prohibited Acts
- Chapter V — Drugs and Devices
- Chapter VIII — Imports and Exports

Volume Two**Appendix II: Federal Regulations****Title 21 CFR — Food and Drug Administration****Subchapter A — General; Part 11 — Electronic Records;****Electronic Signatures**

- Subpart A — General Provisions
- Subpart B — Electronic Records
- Subpart C — Electronic Signatures

Subchapter A — General; Part 50 — Protection of Human Subjects

- Subpart A — General Provisions
- Subpart B — Informed Consent of Human Subjects

Subpart C — [Reserved]

Subpart D — Additional Safeguards for Children in Clinical Investigations

Subchapter A — General; Part 54 — Financial Disclosure by Clinical Investigators**Subchapter A — General; Part 56 — Institutional Review Boards**

- Subpart B — Organization and Personnel
- Subpart C — IRB Functions and Operations
- Subpart D — Records and Reports
- Subpart E — Administrative Actions for Noncompliance

Subchapter D — Drugs for Human Use; Part 312 — Investigational New Drug Application

- Subpart A — General Provisions
- Subpart B — Investigational New Drug Application (IND)
- Subpart C — Administrative Actions
- Subpart D — Responsibilities of Sponsors and Investigators
- Subpart E — Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses
- Subpart F — Miscellaneous
- Subpart G — Drugs for Investigational Use in Laboratory Research Animals or In Vitro Tests
- Subpart H — [Reserved]
- Subpart I — Expanded Access to Investigational Drugs for Treatment Use

Subchapter D — Drugs for Human Use; Part 314 — Applications for FDA Approval to Market a New Drug or an Antibiotic Drug

- Subpart A — General Provisions
- Subpart B — Applications
- Subpart C — FDA Action on Applications
- Subpart D — Hearing Procedures for New Drugs
- Subpart E — Administrative Procedures for Antibiotics
- Subpart F — Miscellaneous Provisions
- Subpart H — Accelerated Approval of New Drugs for Serious Life-threatening Illnesses
- Subpart I — Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible

Subchapter D — Drugs for Human Use; Part 320 — Bioavailability and Bioequivalence Requirements

- Subpart A — General Provisions
- Subpart B — Procedures for Determining the Bioavailability or Bioequivalence of Drug Products

Subchapter D — Drugs for Human Use; Part 330- Over-the-Counter (OTC) Human Drugs Which Are Generally Recognized as Safe and Effective and Not Misbranded

- Subpart A — General Provisions
- Subpart B — Administrative Procedures

Subchapter F — Biologics; Part 601 — Licensing

- Subpart A — General Provisions
- Subpart B — [Reserved]
- Subpart C — Biologics Licensing
- Subpart D — Licensing of Foreign Establishments and Products

Table of Contents

Appendix II (cont'd)

- Subpart E — Accelerated Approval of Biological Products for Serious Life-threatening Illnesses
- Subpart F — Confidentiality of Information
- Subpart G — Postmarketing Studies
- Subpart H — Approval of Biological Products When Human Efficacy Studies Are Not Ethical or Feasible

Subchapter H — Medical Devices; Part 812 —

Investigational Device Exemptions

- Subpart A — General Provisions
- Subpart B — Application and Administrative Action
- Subpart C — Responsibilities of Sponsors
- Subpart D — IRB Review and Approval
- Subpart F — [Reserved]
- Subpart G — Records and Reports

Subchapter H — Medical Devices; Part 814 —

Premarket Approval of Medical Devices

- Subpart A — General
- Subpart B — Premarket Approval Application (PMA)
- Subpart C — FDA Action on a PMA
- Subpart D — [Reserved]
- Subpart E — Postapproval Requirements
- Subpart F — [Reserved]
- Subpart G — [Reserved]
- Subpart H — Humanitarian Use Devices

Title 42 Public Health

Part 50 — Policies of General Applicability

- Subpart F — Promoting Objectivity in Research

Part 93 — Public Health Service Policies on Research

Misconduct

- Subpart A — General
- Subpart B — Definitions
- Subpart C — Responsibilities of Institutions Compliance and Assurances
- Subpart D — Responsibilities of the U.S. Department of Health and Human Services
- Subpart E — Opportunity To Contest ORI Findings of Research Misconduct and HHS Administrative Actions

Title 45 Department of Health and Human Services

Part 160 — General Administrative Requirements

- Subpart A — General Provisions
- Subpart B — Preemption of State Law
- Subpart C — Compliance and Enforcement

Part 164 — Security and Privacy

- Subpart A — General Provisions
- Subparts B-D — [Reserved]
- Subpart E — Privacy of Individually Identifiable Health Information

Part 46 — Protection of Human Subjects

- Subpart A — Federal Policy for the Protection of Human Subjects
- Subpart B — Additional Protections for Pregnant Women, Human Fetuses and Neonates Involved in Research
- Subpart C — Additional Protections Pertaining to Biomedical and Behavioral Research Involving Prisoners as Subjects
- Subpart D — Additional Protections for Children Involved as Subjects in Research

Part 94 — Responsible Prospective Contractors

Appendix III: FDA Guidance

FDA IRB and Clinical Investigator Information Sheets

FDA Internal Compliance Program Guidance Manual (Selected Programs)

FDA Internal Compliance Policy Guides

- Chapter 50 — General Policy
- Chapter 51 — Inspectional

FDA Industry Guidelines

Federal Register Notices

Appendix IV: International Standards

European Union

FDA International Harmonisation Guidelines

Appendix V: Non-FDA Guidance

National Institutes of Health

National Science Foundation

HHS Office for Human Research Protections

Centers for Medicare and Medicaid Services

Non-governmental Guidance

Index

[The next page is Current Contents, Page 35.]